A Case of Successful Third Renal Transplantation Using Rituximab (anti-CD20 Monoclonal Antibody) in a Highly Sensitized Patient / 대한신장학회지
Korean Journal of Nephrology
;
: 646-650, 2007.
Artigo
em Coreano
| WPRIM
| ID: wpr-226297
ABSTRACT
Rituximab, chimeric murine/human anti-CD20 monoclonal antibody, has been currently used as treatment of follicular non-Hodgkins lymphoma and posttransplantation lymphoproliferative disease. Nowadays, rituximab has also been utilized in the renal transplantation to get over acute rejection in highly sensitized patients. We hereby report a case of successful renal transplantation in a highly sensitized patient, who has been done the 3rd renal transplantation. A 44-year-old male patient admitted for the 3rd renal transplantation. His previous 2 transplantations failed because of acute rejection. We tried plasmapheresis and intravenous immunoglobulin, widely used as pretransplantation management in high risk patients. In addition to these, we applied 2 times of rituximab (375 mg/m2) before transplantation at interval of 1 week. The renal function of the patient has been within the normal range without any evidence of rejection 6 months after transplantation.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Valores de Referência
/
Linfoma não Hodgkin
/
Imunoglobulinas
/
Transplante de Rim
/
Plasmaferese
/
Rituximab
/
Rejeição de Enxerto
Limite:
Adulto
/
Humanos
/
Masculino
Idioma:
Coreano
Revista:
Korean Journal of Nephrology
Ano de publicação:
2007
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS